19:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Atara partners with Moffitt Cancer Center to develop CAR T therapies

Atara Biotherapeutics Inc. (NASDAQ:ATRA) partnered with H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) to develop multi‑targeted CAR T immunotherapies to treat cancers with diverse cell types that often become resistant to treatment,...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
11:06 , Sep 8, 2017 |  BioCentury  |  Product Development

Maximizing neoantigens

In conjunction with raising $55 million in a series B round on Friday, Replimune Group Inc. unveiled details of its Immulytic oncolytic virus platform, including next-generation constructs that underpin the company’s strategy for creating multimodal...
00:53 , Jun 8, 2017 |  BC Innovations  |  Emerging Company Profile

Killer expansion

CytoSen Therapeutics Inc.'s nanoparticle technology expands and activates patient-derived NK cells ex vivo with fewer safety risks and manufacturing challenges than other expansion protocols. Unlike T cells, which mount highly specific immune responses to pathogens or...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mucin 1 (MUC1; CD227)

Cancer INDICATION: Cancer Mouse studies suggest chimeric antigen receptor (CAR) T cells targeting a tumor-specific glycoform of MUC1 could help treat cancers that express the glycoform. Primary human T cells were engineered to express a CAR composed...
07:00 , Jun 6, 2016 |  BioCentury  |  Product Development

ASCO by the numbers

ASCO by the numbers Top indications Breast and lung cancer dominate the presentations at this year's American Society of Clinical Oncology (ASCO) meeting, which kicked off on Friday in Chicago. About one-fifth of the 404 breast...
08:00 , Dec 20, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) 4-1BB ligand (4-1BBL; TNFSF9; CD137L) Mouse studies...
08:00 , Feb 4, 2002 |  BC Week In Review  |  Company News

University of Pennsylvania other research news

Scientists reported in Nature Biotechnology the generation of aAPCs and their use in stimulating the growth of cytotoxic T cells (CTLs). aAPCs consisting of an erythromyeloid cell line expressing CD32 and the 4-1BB ligand...